Satoreotide trizoxetan

Star0

DB17158InvestigationalSmall molecule

Satoreotide trizoxetan: Overview.

Mechanism: Pharmacologically active on Somatostatin receptor type 2
Curator reviewed
Formula / weight: C₇₃H₉₅ClN₁₈O₂₁S₂ · 1660.24 g/mol (avg)
Code names: OPS-202

Resolves to

Compound

UNII3M7TX701A4CAS1638746-88-9

Structure

InChIKeyMDDXVKPIPNUPBG-LJLVINLTSA-NSMILES

[H][C@]1(CC2=CC=C(NC(N)=O)C=C2)NC(=O)[C@H](CC2=CC=C(NC(=O)[C@@H]3CC(=O)NC(=O)N3)C=C2)NC(=O)[C@@H](CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](CCCCN)NC1=O)[C@@H](C)O)C(=O)N[C@H](CC1=CC=C(O)C=C1)C(N)=O)NC(=O)[C@H](CC1=CC=C(Cl)C=C1)NC(=O)CCC(N1CCN(CC(O)=O)CCN(CC(O)=O)CC1)C(O)=O

Targets

P30874SSTR2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Satoreotide trizoxetan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account